<DOC>
	<DOC>NCT01794780</DOC>
	<brief_summary>This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world.</brief_summary>
	<brief_title>A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<criteria>Willing and able to provide informed consent Physiciandiagnosis of COPD COPD patients requiring longacting bronchodilator treatment Patients with spirometry available at baseline Patients who have a diagnosis of asthma. Patients who had been hospitalized for a COPD exacerbation in the 4 weeks prior to Visit 1. Current clinical diagnosis of other chronic respiratory illnesses Concurrent participation in a clinical trial or use of an investigational drug. Active malignancy or history of malignancy of any organ system Pregnant or nursing (lactating) women Women of childbearing potential with no contraception Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>